Lyra Therapeutics, Inc.

LYRA

US55234L1052

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
0.3335 ^USD	+2.46%		-10.59%	-93.64%

05-21	Lyra Therapeutics Reduces Workforce to Extend Cash Runway	MT
05-21	Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	CI

Laura Edgerly-Pflug Ceases to Be Senior Vice President of Technical Operations of Lyra Therapeutics, Inc

July 24, 2020 at 09:28 pm

Effective July 24, 2020, Laura Edgerly-Pflug ceased to be the Senior Vice President of Technical Operations of Lyra Therapeutics, Inc. (the Company) and her employment with the Company terminated.

Latest news about Lyra Therapeutics, Inc.

Lyra Therapeutics Reduces Workforce to Extend Cash Runway	05-21	MT
Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	05-21	CI
Lyra Therapeutics, Inc. Announces Cost-Cutting Measures to Preserve Capital	05-21	CI
Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50	05-07	MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy	05-07	MT
Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell	05-06	MT
Lyra Therapeutics Lead Drug Candidate Fails in Phase 3 Study	05-06	DJ
Lyra Therapeutics, Inc. Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis	05-06	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
Lyra Therapeutics, Inc. Announces Board Changes	04-19	CI
Lyra Therapeutics Files $300 Million Mixed Shelf Offering	03-22	MT
Lyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Lyra Therapeutics, Inc Announces Appointment of Ronan O?Brien as Chief Legal Officer	16/10/23	CI
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target	06/10/23	MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating	12/09/23	MT
Lyra Therapeutics Says Phase 2 Trial for Chronic Rhinosinusitis Treatment Meets Primary Endpoint	12/09/23	MT
Transcript : Lyra Therapeutics, Inc. - Special Call	12/09/23
Lyra Therapeutics Announces Positive Topline Results from Beacon Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis in Patients with Prior Ethmoid Sinus Surgery	12/09/23	CI
HC Wainwright Starts Lyra Therapeutics at Buy With $12 Price Target	31/08/23	MT
North American Morning Briefing : China Angst -2-	15/08/23	DJ
Lyra Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/08/23	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell Microcap Value Index	23/06/23	CI
Lyra Therapeutics, Inc.(NasdaqGM:LYRA) added to Russell 3000E Value Index	23/06/23	CI
North American Morning Briefing : Stock Futures Point to Steady Open; Saudi Cuts Boost Oil	05/06/23	DJ

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.

Sector

Biotechnology & Medical Research

Calendar

13/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Lyra Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.3335 USD

Average target price

4.5 USD

Spread / Average Target

+1,249.33%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LYRA THERAPEUTICS, INC.	-93.64%	19.84M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research

Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Biotechnology & Medical Research

Laura Edgerly-Pflug Ceases to Be Senior Vice President of Technical Operations of Lyra Therapeutics, Inc

Latest news about Lyra Therapeutics, Inc.

Chart Lyra Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Lyra Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research